XOMA XOMA Ltd., featured news, full reports, and detailed XOMA.O charts.
XOMA Ltd. (XOMA) Wrap Up:
XOMA Ltd. (âXOMAâ or the âCompanyâ), a Bermuda company, is a leading biopharmaceutical company focused on the discovery, development and manufacture of therapeutic antibodies. XOMA uses its expertise, technologies and capabilities to build a product pipeline that includes multiple proprietary and collaborative development programs. The Companyâs lead product candidate is XOMA 052, a high affinity anti-IL-1 beta antibody with the potential to treat multiple inflammatory diseases of large unmet need. XOMA 052 is currently in Phase 1 clinical studies of Type 2 diabetes patients. XOMA has multiple revenue streams and generates revenues from product royalties, technology licenses, development collaborations and biodefense contracts. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f11%2f0001193125-08-052901.html#FIS_BUSINESS"
XOMA Ltd. (XOMA*(D):NASDAQ)
Snapshot of XOMA Ltd. (XOMA)
|
OPEN
$0.75
|
PREVIOUS CLOSE
$0.74
|
|
|
DAY HIGH
$0.78
|
DAY LOW
$0.75
|
|
|
52 WEEK HIGH
06/8/09 - $1.34
|
52 WEEK LOW
03/12/09 - $0.37
|
|
|
MARKET CAP
151.6M
|
AVERAGE VOLUME 3 mo
2.1M
|
|
|
DILUTED EPS TTM
$-0.10
|
SHARES OUTSTANDING
198.9M
|
|
|
XOMA Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
XOMA Details
XOMA Ltd., a biopharmaceutical company, engages in the discovery, development, and manufacture of therapeutic antibodies and other agents to treat inflammatory, autoimmune, infectious, and oncological diseases. The company receives royalties on three approved products: RAPTIVA, which is marketed globally for the treatment of chronic moderate-to-severe plaque psoriasis; LUCENTIS, which is marketed globally for the treatment of neovascular (wet) age-related macular degeneration; and CIMZIA, which is approved in the U.S. and Switzerland for the treatment of Crohns disease. Its products under development include XOMA 052, a monoclonal antibody for the treatment of Type 2 diabetes, rheumatoid arthritis, systemic juvenile idiopathic arthritis, and gout, which is in Phase 1 clinical studies; and XOMA 3AB, a biodefense anti-botulism antibody for the treatment of botulism poisoning. The companys developing products also include HCD122, a human anti-CD40 antagonist antibody for the treatment for B-cell mediated diseases, including malignancies and autoimmune diseases in Phase 1 and Phase 2 clinical trials for various indications. In addition, it licenses proprietary technologies relating to bacterial expression of recombinant pharmaceutical products to biotechnology and pharmaceutical companies. The company has collaboration agreements with Genentech, Inc.; UCB Celltech; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Schering-Plough Research Institute; Novartis AG; and Arana Therapeutics Limited. XOMA Ltd. was founded in 1981 and is headquartered in Berkeley, California.
XOMA Top Compensated Officers
Executives, Board Directors
Key developments for XOMA Ltd. (XOMA)
XOMA Ltd. announced that they will report Q3, 2009 results before the start of trading on November 09, 2009.
XOMA Ltd., Q3 2009 Earnings Call, Nov-09-2009
XOMA Ltd. expected to Report Fiscal Year 2009 Results on March 8, 2010. This event was calculated by Capital IQ (Created on November 3, 2009).
XOMA Competitors
| Company | Last | Change |
| Celera Group | $6.35 USD | 0.00 |
| Diamyd Medical AB | kr134.25 SEK | -0.75 |
| OSI Pharmaceuticals Inc | $33.32 USD | +0.18 |
| QLT Inc | C$3.88 CAD | +0.13 |
| Seattle Genetics Inc | $9.45 USD | -0.07 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | XOMA | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 1.2x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 0.7x |
|
|
XOMA |
||
XOMA transactions
| Type Date |
Target |
|
Private Placement
June 5, 2009 |
-- |
|
Private Placement
May 15, 2009 |
-- |
More Recent News About XOMA Ltd.
-
RidgewaterEquity.com Free Fundamental Sector & Market Research on SAH, WR, RTP, YSI, TSO and XOMA
RidgewaterEquity.com inspires to bring the best from the internet under one roof, providing you with a one click option to view what the market,...
Market Wire, 11/04/09 · More from publication